Braveheart Bio Q3 2026 Results: Net Loss of $26.5M, Loss Narrows
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead candidate BHB-1893 for hypertrophic cardiomyopathy (HCM). The company reports a limited operating history with significant losses and expects to require substantial additional funding to support its ongoing clinical trials, including LIONHEART-HCM and TRUEHEART-HCM.
- Key figure
- Net loss $26.5M